Guangzhou Aige Biotechnology

Guangzhou Aige Biotechnology is a clinical-stage biotechnology company based in Guangzhou, China, dedicated to the development of transformative cell therapies for autoimmune diseases. The company specializes in Chimeric Antigen Receptor T-cell (CAR-T) technology, specifically engineering cells to target B-cell mediated pathologies. Its lead candidate, Aige-001, is a CD19-targeted CAR-T therapy currently in Phase 1 clinical development for the treatment of refractory Systemic Lupus Erythematosus (SLE). Aige Biotechnology aims to provide long-term, drug-free remission for patients who have failed conventional immunosuppressive treatments. The company operates within the Guangzhou High-tech Industrial Development Zone, leveraging local academic and clinical infrastructure to accelerate its pipeline.